Source:

Healio Interview

Disclosures: Jacobs reports receiving research funding from Pharmacyclics and TG Therapeutics, Inc. and speakers' bureau fees from AbbVie, AstraZeneca, Genentech, Janssen Pharmaceuticals and Pharmacyclics and serving on advisory boards for AbbVie and Pharmacyclics.
November 25, 2020
1 min watch
Save

New agents change treatment landscape in CLL

Source:

Healio Interview

Disclosures: Jacobs reports receiving research funding from Pharmacyclics and TG Therapeutics, Inc. and speakers' bureau fees from AbbVie, AstraZeneca, Genentech, Janssen Pharmaceuticals and Pharmacyclics and serving on advisory boards for AbbVie and Pharmacyclics.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Ryan W. Jacobs, MD, discussed how new therapeutic options, particularly small molecule inhibitors, have impacted the treatment landscape in chronic lymphocytic leukemia.

“It’s really great for our CLL patients to have these more effective and, by and large, well-tolerated treatment options,” Jacobs, head of the clinical trials program for CLL at Atrium Health’s Levine Cancer Institute, said.

 

Click here for the next video in this series.

click me